| 摘要 |
The use of a pegylated interferon-alfa and a CCR5 antagonist, further in association with at least one of ribavirin, IL-2, IL-12, pentafuside alone or in combination with an anti-HIV-1 drug therapy, e.g., HAART, for preparation of a medicament for the treatment of HIV-1 infections as well as HIV-1 infections as well as HIV-1 and HCV co-infections in treatment-naive as well as treatment-experienced adult and pediatric patients are disclosed.
|
